Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using VEGF-targeting Agent

Review the clinical trials studying vegf-targeting agent on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 127

Testing Olaparib for One or Two Years, with or without Bevacizumab, to Treat Ovarian Cancer
Status: Active
Location: 625 locations
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Status: Active
Location: 557 locations
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Status: Active
Location: 53 locations
Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma
Status: Active
Location: 37 locations
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Status: Active
Location: 35 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Status: Active
Location: 22 locations
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Status: Active
Location: 20 locations
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Status: Active
Location: 16 locations
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Status: Active
Location: 16 locations
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Status: Active
Location: 14 locations
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Status: Active
Location: 22 locations
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Status: Active
Location: 13 locations
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Status: Active
Location: 13 locations
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Status: Active
Location: 14 locations
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination with Chemotherapy Treatment (FOLFOX plus Bevacizumab) in Metastatic Colorectal Cancer
Status: Active
Location: 13 locations
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Status: Active
Location: 13 locations
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 14 locations
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Status: Active
Location: 14 locations
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Status: Active
Location: 11 locations
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Status: Active
Location: 12 locations
First in Human Study of AZD9592 in Solid Tumors
Status: Active
Location: 10 locations
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Status: Active
Location: 10 locations
Carboplatin, Pemetrexed, and Bevacizumab with or without Atezolizumab for the Treatment of Stage IV Non-squamous Non-small Cell Lung Cancer
Status: Active
Location: 9 locations
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Status: Active
Location: 11 locations
A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors
Status: Active
Location: 9 locations